| [1] |
Gradl G. 2023. Im Jahr 2022 wurden 72 % mehr orale Tumortherapeutika zulasten der GKV abgegeben als im Jahr 2013. www.dapi.de/aktuelles/zahl-des-monats/im-jahr-2022-wurden-72-mehr-orale-tumortherapeutika-zulasten-der-gkv-abgegeben-als-im-jahr-2013 (accessed on 21 October 2024) |
| [2] |
Travi C, Würstlein R. 2021. Orale tumortherapie beim mammakarzinom. |
| [3] |
Dong C, Wu J, Chen Y, Nie J, Chen C. 2021. Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer. |
| [4] |
Heyn G. 2015. Orale Onkologika-besonderer Beratungsbedarf. Pharmazeutische Zeitung 160(35):2606−2611 |
| [5] |
Schlichtig K, Dürr P, Dörje F, Fromm MF. 2019. New oral anti-cancer drugs and medication safety. |
| [6] |
Hirschberg L, Henze F, Paradies K, Winkler S, Schinköthe T, et al. 2025. Evaluation of therapy support through a standardized nursing consultation for patients undergoing oral tumor therapy in gynecological oncology within the prospective CAMPA initiative. |
| [7] |
Welslau M, Tesch H. 2022. OncoCoaching - eine patientenzentrierte versorgung in der onkologie. |
| [8] |
Zamora P, Riese C, Borges U, Baumann W, Schmitz S. 2014. Patientenkompetenz in der oralen krebstherapie (PACOCT). |
| [9] |
Shumilov E, Vehling-Kaiser U, Damnali G, Schulz X, Kaiser U, et al. 2022. Oral and subcutaneous anticancer therapy training course for non-physician healthcare professionals: a survey evaluating the relevance of its content and its implications in the practice of cancer care. |
| [10] |
CANKADO. https://cankado.com (accessed on 5 October 2024) |
| [11] |
LamaPoll. www.lamapoll.de (accessed on 5 October 2024) |
| [12] |
Daikeler J, Bošnjak M, Lozar Manfreda K. 2020. Web versus other survey modes: an updated and extended meta-analysis comparing response rates. |
| [13] |
Hirschl N, Leveque W, Granitto J, Sammarco V, Fontillas M, et al. 2024. PARP inhibitors: strategic use and optimal management in ovarian cancer. |
| [14] |
Henze F, Bornemann K, Haupt J, König A, Ortner P, et al. 2023. Interprofessionelles management der oralen tumortherapie. |
| [15] |
Harbeck N, Haupt J, Henze F, Koenig A, Lippach K, et al. 2022. Pflegeexpertinnen begleiten orale Tumortherapie. Die Schwester Der Pfleger 60(9):42−47 |
| [16] |
Sheer B, Wong FK. 2008. The development of advanced nursing practice globally. |
| [17] |
Carnwell R, Daly WM. 2003. Advanced nursing practitioners in primary care settings: an exploration of the developing roles. |
| [18] |
Harbeck N, Fasching PA, Wuerstlein R, Degenhardt T, Lüftner D, et al. 2023. Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial. |
| [19] |
Würstlein R, Wolff J, Harbeck N, Wülfing P. 2025. Digitale begleitung der therapie und nachsorge beim mammakarzinom. |